Associated Papers
A Comparative Study on the Multidimensional Features of Hereditary and Sporadic Medullary Thyroid Carcinoma Patients: A Single-Center Retrospective Study.
Deniz MS et al.
Medicina (kaunas, Lithuania), 2025
Understanding the variant landscape, and genetic epidemiology of Multiple Endocrine Neoplasia in India.
Vatsyayan A et al.
Endocrine, 2024
KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential.
Eser M et al.
Scientific Reports, 2024
Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness.
Shirali AS et al.
Journal of the Endocrine Society, 2024
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
Subbiah V et al.
Npj Precision Oncology, 2024
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
Blood Liquid Biopsy in an Advanced Medullary Thyroid Carcinoma: A Case Study with Rearranged during Transfection Heterogeneity.
Gumà J et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2023
Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib.
Elisei R et al.
The Journal of Clinical Endocrinology and Metabolism, 2022
Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors-A Retrospective Multi-Center Registry Analysis.
Koehler VF et al.
Cancers, 2022
Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies.
Wang S et al.
Frontiers in Oncology, 2020
Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing.
Ciampi R et al.
Iscience, 2019
Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients.
Pezzani R et al.
International Journal of Endocrinology, 2019
Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.
Lier A et al.
Jco Precision Oncology, 2018
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases.
Romei C et al.
Oncotarget, 2018
New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.
Romei C et al.
Journal of Medical Genetics, 2016
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA et al.
Endocrine-related Cancer, 2015
Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma.
Welander J et al.
The Journal of Clinical Endocrinology and Metabolism, 2014